Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.
Bartalucci, C., Baldi, F., Ricci, E., Orofino, G., Menzaghi, B., Ferrara, S., et al. (2024). People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?. AIDS, 38(3), 430-434 [10.1097/qad.0000000000003766].
People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?
Cascio, Antonio;
2024-03-01
Abstract
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.
| File | Dimensione | Formato | |
|---|---|---|---|
|
eople with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy.pdf
Solo gestori archvio
Tipologia:
Versione Editoriale
Dimensione
652.77 kB
Formato
Adobe PDF
|
652.77 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
